The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts

Description

To learn whether a new imaging technology, Contrast-Enhanced Mammography (CEM), compared to standard mammography, can better detect breast cancers in women with dense breasts

Conditions

Breast Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

To learn whether a new imaging technology, Contrast-Enhanced Mammography (CEM), compared to standard mammography, can better detect breast cancers in women with dense breasts

The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts

The C-MERIT Screening Cohort: Contrast-enhanced Mammography for Breast Cancer Screening and Risk Assessment in Women With Dense Breasts

Condition
Breast Cancer
Intervention / Treatment

-

Contacts and Locations

Houston

M D Anderson Cancer Center, Houston, Texas, United States, 77030

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Female patients 30-75 years of age with dense breasts (ACR BI-RADS categories C and D) who undergo routine yearly mammography at participating MDACC sites
  • 2. Willingness to co-enroll or currently enrolled in PA17-0584
  • 3. Willingness to participate in the study and ability to provide informed consent
  • 1. Self-reported new breast symptoms since last mammogram including nipple discharge, palpable mass, skin dimpling, or focal pain.
  • 2. Current or recent (within the prior 6 months) history of pregnancy or breast feeding
  • 3. Personal history of breast cancer (DCIS or invasive breast cancer)
  • 4. Treatment of any other type of cancer within the past 5 years excluding in-situ cervical and non-melanoma skin cancer
  • 5. Breast biopsy within 6 months
  • 6. Breast surgery within 12 months
  • 7. Breast MRI, MBI, or CEM performed within 24 months
  • 8. Known allergy to iodine-containing contrast agents
  • 9. History of anaphylactic reaction to any substance that required hospitalization or IV placement in a patient with no known prior uneventful exposure to iodine-based IV contrast
  • 10. Renal insufficiency (as defined by UTMDACC policy 3.30- attachment 1 (appendix D)

Ages Eligible for Study

30 Years to 75 Years

Sexes Eligible for Study

FEMALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

M.D. Anderson Cancer Center,

Olena Weaver, MD, PRINCIPAL_INVESTIGATOR, M.D. Anderson Cancer Center

Study Record Dates

2027-12-31